Previous 10 | Next 10 |
REDWOOD CITY, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced a presentation highlighting the role of an enzymatic approach to support RNA-based therapeutics manufacturing at the TIDES Europe annual meeting taking place...
2023-10-21 03:29:32 ET Summary Cathie Wood and ARK Investment Management have abandoned their "soft landing" theory and are actively preparing for other scenarios. ARK now expects an "economic landing stronger than soft", while facing more than a billion in net fund outflows since...
REDWOOD CITY, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the third quarter of 2023 on Thursday, November 2, 2023, following the close of market. Codexis management will...
2023-10-05 14:11:41 ET Summary Codexis, Inc. is undergoing a significant restructuring to reduce costs, refocus its developmental efforts and streamline its organization. The company's ECO platform to provide enzymes for RNA therapeutics shows some potential, but the company's cas...
REDWOOD CITY, Calif., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced President and Chief Executive Officer Stephen Dilly, MBBS, PhD, has been named the winner of the prestigious 2023 Bloom Burton Award. Dr. Dilly was recogniz...
REDWOOD CITY, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Codexis, has been named a finalist for the prestigious 2023 Bloom Burton Award. Bestowed ...
2023-09-13 10:42:13 ET More on Codexis Seeking Alpha’s Quant Rating on Codexis Historical earnings data for Codexis Financial information for Codexis Codexis announces a San Carlos facility lease that could potentially save $30M For further det...
REDWOOD CITY, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the Cantor Global Healthcare Conference, being held September 26-28, 2023, in New York, New York. Management will participate ...
2023-09-08 07:08:22 ET More on Codexis Seeking Alpha’s Quant Rating on Codexis Financial information for Codexis For further details see: Codexis announces a San Carlos facility lease that could potentially save $30M
REDWOOD CITY, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company has executed an Assignment and Assumption of Lease for its San Carlos, California location. As a result of consolidating operations to its headq...
News, Short Squeeze, Breakout and More Instantly...
REDWOOD CITY, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with Crosswalk Therapeutics for the Company’s investigational Fabry and Pompe disease compounds. Under...
2024-05-30 07:30:04 ET Cantor Fitzgerald analyst issues OVERWEIGHT recommendation for CDXS on May 30, 2024 06:15AM ET. CDXS was trading at $3.19 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy rec...
2024-05-30 07:00:11 ET Kristen Kluska from Cantor Fitzgerald issued a price target of $11.00 for CDXS on 2024-05-30 06:15:00. The adjusted price target was set to $11.00. At the time of the announcement, CDXS was trading at $3.19. CDXS currently trades -34.90% versus its...